Search details
1.
An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.
Front Immunol
; 14: 1117466, 2023.
Article
in English
| MEDLINE | ID: mdl-36911725
2.
Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV.
Front Oncol
; 12: 1023015, 2022.
Article
in English
| MEDLINE | ID: mdl-36483037
3.
Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms.
Front Oncol
; 11: 637420, 2021.
Article
in English
| MEDLINE | ID: mdl-33718228
4.
An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma.
Oncoimmunology
; 10(1): 1975889, 2021.
Article
in English
| MEDLINE | ID: mdl-38283034
5.
Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.
Front Immunol
; 11: 595035, 2020.
Article
in English
| MEDLINE | ID: mdl-33240282
6.
[Therapeutic cancer vaccination for treatment of haematological cancers].
Ugeskr Laeger
; 181(20A)2019 Oct 14.
Article
in Danish
| MEDLINE | ID: mdl-31610839
7.
Cancer immune therapy for lymphoid malignancies: recent advances.
Semin Immunopathol
; 41(1): 111-124, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30006739
8.
[Cancer immune therapy for the treatment of haematological malignancies].
Ugeskr Laeger
; 181(10)2019 Mar 04.
Article
in Danish
| MEDLINE | ID: mdl-30869069
9.
High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.
Blood Cancer J
; 9(2): 8, 2019 01 17.
Article
in English
| MEDLINE | ID: mdl-30655510
10.
Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies.
Front Immunol
; 9: 2264, 2018.
Article
in English
| MEDLINE | ID: mdl-30327655
11.
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.
Oncoimmunology
; 7(2): e1390641, 2018.
Article
in English
| MEDLINE | ID: mdl-29308318
Results
1 -
11
de 11
1
Next >
>>